Search results
Showing 526 to 537 of 537 results for meta analysis
Omalizumab for previously treated chronic spontaneous urticaria (TA339)
Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.
Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care (HTG607)
Evidence-based recommendations on Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care.
The PediGuard for placing pedicle screws in spinal surgery (MIB26)
NICE has developed a medtech innovation briefing (MIB) on the PediGuard for placing pedicle screws in spinal surgery
Evidence-based recommendations on axitinib (Inlyta) for previously treated advanced renal cell carcinoma in adults.
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)
Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis in adults.
Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack.
LARS for reconstructing damaged intra-articular cruciate knee ligaments (MIB30)
NICE has developed a medtech innovation briefing (MIB) on LARS for reconstructing damaged intra-articular cruciate knee ligaments
Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.
NICE is making changes to simplify our offer to the life sciences industry.
Jeanette Kusel explains how we are working in partnership to improve patient access to the best digital health innovations.
More evidence needed to recommend Type 2 diabetes treatment tirzepatide
More evidence is needed on the clinical and cost-effectiveness of a new treatment option for people with type 2 diabetes before it could be recommended for NHS use
Following the successful evaluation of Zio XT, developers of digital health technologies are encouraged to engage with NICE through one of several different routes.